8. Sponsored Research and Clinical Trial Agreements

Aevitas

In 2018, Aevitas entered into a Sponsored Research Agreement (“SRA”) with the University of Massachusetts (“UMass SRA”) for certain continued research and development activities related to the development of adeno-associated virus (“AAV”) gene therapies in complement-mediated diseases and with the Trustees of the University of Pennsylvania (“UPenn SRA”) for certain continued research and development activities related to the development of AAV gene therapies in complement-mediated diseases. For the three and six months ended June 30, 2019 and 2018, Aevitas recorded the following expense in research and development for sponsored research and clinical trial agreements:

Cellvation

For the three and six months ended June 30, 2019 and 2018, respectively, Cellvation recorded expense of $0.1 million and $0.1 million and $0.1 million and $0.1 million, respectively in connection with its sponsored research arrangement with the University of Texas. The expense was recorded in research and development expense in the Condensed Consolidated Statements of Operations.

Mustang

For the three and six months ended June 30, 2019 and 2018, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements: